Physician profile
Christopher Thomas Raczynski
NPI 1689866410
$1,679.41
in general payments reported to CMS, 2019-2025
15 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $283 · 2021: $180 · 2022: $22.42 · 2023: $23.32 · 2024: $62.63 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $293.18 | 2024-2025 | Sublocade |
| Allergan, INC. | $206.28 | 2019-2020 | |
| Shire North American Group INC | $187.48 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $176.07 | 2019-2020 | |
| Lundbeck LLC | $150.82 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $140.73 | 2021 | |
| Bausch Health US, LLC | $105.76 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $85.57 | 2019 | |
| Alkermes, INC. | $75.65 | 2019-2020 | |
| Abbvie INC. | $66.30 | 2021-2023 | |
| Adlon Therapeutics L.P. | $45.69 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $45.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.26 | 2020 | |
| Neos Therapeutics, LP | $33.75 | 2019 | |
| Titan Pharmaceuticals, INC. | $25.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Raczynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.